DE69430521D1 - Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension - Google Patents

Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension

Info

Publication number
DE69430521D1
DE69430521D1 DE69430521T DE69430521T DE69430521D1 DE 69430521 D1 DE69430521 D1 DE 69430521D1 DE 69430521 T DE69430521 T DE 69430521T DE 69430521 T DE69430521 T DE 69430521T DE 69430521 D1 DE69430521 D1 DE 69430521D1
Authority
DE
Germany
Prior art keywords
glaucoma
treatment
analogues
prostagrandin
ocular hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430521T
Other languages
English (en)
Inventor
Verney L Sallee
Desantis, Jr
Paul W Zinke
John E Bishop
Peter G Klimko
Robert D Selliah
Thomas R Dean
Mark R Hellberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/167,470 external-priority patent/US5721273A/en
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of DE69430521D1 publication Critical patent/DE69430521D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69430521T 1993-12-15 1994-12-10 Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension Expired - Lifetime DE69430521D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16774793A 1993-12-15 1993-12-15
US08/167,470 US5721273A (en) 1993-12-15 1993-12-15 Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US31667294A 1994-09-30 1994-09-30

Publications (1)

Publication Number Publication Date
DE69430521D1 true DE69430521D1 (de) 2002-06-06

Family

ID=27389393

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430521T Expired - Lifetime DE69430521D1 (de) 1993-12-15 1994-12-10 Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension

Country Status (4)

Country Link
EP (2) EP0667160B1 (de)
AT (1) ATE216889T1 (de)
AU (1) AU687906B2 (de)
DE (1) DE69430521D1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5866602A (en) * 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5994397A (en) * 1995-12-22 1999-11-30 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) * 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
AU734789B2 (en) * 1996-11-01 2001-06-21 Alcon Laboratories, Inc. Use of a combination of carbonic anhydrease inhibitors and prostaglandins for treating glaucoma
US6353000B1 (en) * 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
NZ521325A (en) * 2000-03-16 2004-05-28 Sucampo Ag Use of prostaglandins for the treatment of ocular hypertension and glaucoma
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
MXPA04001604A (es) * 2001-08-23 2004-07-08 Sucampo Ag Metodo y composicion para tratamiento de hipertension ocular y glaucoma.
JP2005519978A (ja) * 2002-03-28 2005-07-07 スキャンポ・アーゲー 高眼圧症および緑内障の処置方法
JP2018536017A (ja) 2015-09-22 2018-12-06 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための化合物及び組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IL87116A (en) * 1987-07-17 1993-03-15 Schering Ag 9-halogen-(z)-prostaglandin derivatives and pharmaceutical compositions containing the same
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4036140A1 (de) * 1990-11-09 1992-05-14 Schering Ag 9-halogen-11ss-hydroxy-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE4229053A1 (de) * 1992-08-31 1994-03-03 Schering Ag Verwendung von Estern und Amiden von 9-Chlor-Prostaglandinen für die Herstellung von Arzneimitteln zur Förderung der Hautdurchblutung
DK0656889T3 (da) * 1992-08-31 1999-03-22 Schering Ag 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler

Also Published As

Publication number Publication date
AU687906B2 (en) 1998-03-05
AU7913894A (en) 1995-06-22
EP0667160A3 (de) 1995-11-15
EP0667160B1 (de) 2002-05-02
EP1088816A2 (de) 2001-04-04
EP0667160A2 (de) 1995-08-16
ATE216889T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE420857T1 (de) Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
ATE286880T2 (de) Verwendung von fluprostenolisopropylester zur herstellung eines arzneimittels zur behandlung von glaukom und okularer hypertension
DE69634414D1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
ATE480240T1 (de) Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
DE69430521D1 (de) Anwendung von Prostagrandin-Analogen für die Behandlung von Glaukome und okuläre Hypertension
ATE273009T1 (de) Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
ATE223200T1 (de) Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
DE69106777D1 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
DE60012163D1 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck
ATE228014T1 (de) Zusammensetzungen und ihre anwendungen gegen die hyperakute abstossung von transplantaten und bestimmte krankheiten

Legal Events

Date Code Title Description
8332 No legal effect for de